(Date:7/25/2008)...on Significant Improvements in Members, Health, A... leader in health,care quality management solution...it has entered into a long-term agreement with Wel...aboration on Quality(SM) Incent and,Reward Best Pr...rk and,primary care clinicians to promote improved...
(Date:7/25/2008)...ire/ -- The Elekta Family of Companies will,showca... at the 2008,American Association of Physicists in... the joint forces of Elekta, IMPAC and CMS are del...d delivery solutions that,streamline the treatment...s, as well as enhance clinician efficiency., "Our...
(Date:7/25/2008)...esophagus can cause immune system changes , ...t evidence linking gastroesophageal reflux disease...versity Medical Center researchers. , An associ...n the 1970s, and since then studies have shown tha...ents also experience GERD symptoms. But the actual...
(Date:7/25/2008)... Retina Group of New York will present an educatio...tion especially designed for seniors. The lecture ...116 Merritts Road, Farmingdale, NY 11735, 1:00 to ... and refreshments will be provided. The phone numb... Hicksville and Hauppauge, NY (...
Breaking Medicine News(10 mins):Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3(Date:7/23/2008)... Systemic Therapy to Treat the Disease -, WAYNE, ...irstCall/ --,Bayer HealthCare Pharmaceuticals and ...nounced that The New England Journal of Medicine p...that Nexavar(R) (sorafenib),tablets decreased the ...ith,unresectable hepatocellular carcinoma (HCC), o...
(Date:7/23/2008)...wire-USNewswire/ -- The following was,released by ..., Ranking Member Smith, and Members of the Committ...., Since I appeared before this Committee almost ...ed with the talented and dedicated professionals,a..., and I have come to,appreciate that much more dee...
(Date:7/23/2008)...ewswire/ -- InCode BioPharmaceutics, Inc.,an emer...eclinical test,results demonstrating the utility o...t of the rare chronic blood disorder paroxysmal no... will be presented at the XXII,International Compl...,2008., The only treatment currently available f...
(Date:7/22/2008)...2 /- Following a,thorough r...Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: ... PI-88 phase 3 study in liver cancer. Progen confi...ng portfolio of compounds and,the company will act...ortunities through Merger & Acquisition activity.,...
Breaking Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Diabetes in the Bedroom 3A Scarier than Halloween 3F 2844 1Diabetes in the Bedroom 3A Scarier than Halloween 3F 2844 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 1Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 3Figure Skater Peggy Fleming Teams With HealthSaver 3A Cook Your Way to a Healthy Diet 2841 4Prime Therapeutics Announces URAC Accreditation 2840 1Prime Therapeutics Announces URAC Accreditation 2840 2GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 1GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 2GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 3GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 4GainSpan Unveils Wi Fi 28R 29 Sensor Network Solution With Years of Battery Life 2837 5... Statistically Significant Changes in,Agitation Le...6, 2007 /PRNewswire-FirstCall/ --,Alexza Pharmaceu...lts from its Phase IIa clinical trial of AZ-004 (S...h acute agitation. The 10 mg,dose of AZ-004 met th...s a statistically-significant reduction in the mea...
...esented at Keystone Scientific Meeting, SOUTH SAN ...tCall/ -- Rigel today announced that Yonchu,Jenkin...presenting,on the company,s efforts to develop a s...he Human Immunodeficiency Virus (HIV),infection at...ch,27th and 29th. Dr. Jenkins will present both a ...
Other Medicine Technology:Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 2Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 4Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 5Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 6Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV,Activity 2Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV,Activity 3Horizontal Mini Gel Kit. Gel Bed dimensions: 7.5cm(w) x 10cm(l). Includes one comb and tapered baffles for casting in the unit. Gel bed is UV transparent. Available in clear, blue, yellow, pink,
... gels offer many advantages for nucleic acid separ...cular biologist. Agarose gels are easy to cast and...nderlaying and prevent electrical field discontinu...Horizontal systems are more economical and easier ...
The Mini-Sub cell GT system, with 7 x 10 cm tray, is used for submerged horizontal gel electrophoresis of nucleic acids in mini format 7 x 10 cm agarose gels. The system includes an electrophoresis c
Wide Mini ReadySub-Cell GT Cell, includes buffer tank, lid and electrodes, leveling bubble; accommodates 20-well, 32-well, and 2 x 32-well wide mini ReadyAgarose gels
Medicine Products: